
Join to View Full Profile
450 Brookline AveBoston, MA 02215
Phone+1 617-632-3000
Dr. O'Donnell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2010 - 2014
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2007 - 2010
Vanderbilt University School of MedicineClass of 2007
Certifications & Licensure
FL State Medical License 2024 - Present
MA State Medical License 2009 - 2027
ME State Medical License 2020 - 2027
NH State Medical License 2024 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
- 3 citationsOncologist perspective: role of imaging in myeloma.Yael N Shapiro, Elizabeth O'Donnell
Skeletal Radiology. 2022-01-01 - 17 citationsLifestyle considerations in multiple myelomaYael N Shapiro, Jeffrey Peppercorn, Andrew Yee, Andrew R. Branagan, Noopur Raje
Blood Cancer Journal. 2021-10-26 - 56 citationsLong-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.Jorge J. Castillo, Kirsten Meid, Joshua Gustine, Carly Leventoff, Timothy P White
Leukemia. 2021-09-16
Abstracts/Posters
- Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for ImmunotherapyElizabeth K. O'Donnell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple MyelomaElizabeth K. O'Donnell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple MyelomaElizabeth K. O'Donnell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Vail Symposium Kicks off Summer Season with Program in Conjunction with Shaw Cancer CenterMay 23rd, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









